Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 10;12:689472. doi: 10.3389/fimmu.2021.689472

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Smith and Burger

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The B cell receptor (BCR) signaling pathway and acquired, primary, driver Gain-of-Function (GoF) mutations found in CLL and other BTKi-sensitive malignancies . CD79A and B GoF, found in WM and ABC-type DLBCL, and very rare in CLL, are labeled with yellow contour. Signaling proteins marked with indicate those affected by primary GoF mutations in adult T cell leukemia as reported (103). The MYD88 L265P GoF mutation in 95% of WM patients, and also in ABC-type DLBCL, and in some CLL patients induces an activated endolysosome containing TLR9 and the BCR.

Inline graphic — The B cell receptor (BCR) signaling pathway and acquired, primary, driver Gain-of-Function (GoF) mutations found in CLL and other BTKi-sensitive malignancies . CD79A and B GoF, found in WM and ABC-type DLBCL, and very rare in CLL, are labeled with yellow contour. Signaling proteins marked with indicate those affected by primary GoF mutations in adult T cell leukemia as reported (103). The MYD88 L265P GoF mutation in 95% of WM patients, and also in ABC-type DLBCL, and in some CLL patients induces an activated endolysosome containing TLR9 and the BCR.